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Abstract The prevalence of chronic viral infectious diseases, the emergence and re-emergence of new viral
infections, and in particular, resistance to currently used antiviral drugs have led to increased demand
for new antiviral strategies and reagents. Increased understanding of the molecular mechanisms of viral
infection has provided great potential for the discovery of new antiviral agents that target viral proteins
or host factors. In this work, we introduce a comprehensive system using enteroviruses 71 (EV71) as an
example for leading compound discovery to develop new antiviral.
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INTRODUCTION
Viruses constitute a large family of pathogens to cause
severe infectious diseases throughout human, animal, plant
and bacteria. Over the past decades, antiviral agents that
target viral proteins or host factors have been successfully
developed. Based on their inhibitory mechanisms, antiviral
reagents can be divided into three groups, i.e., virus-
targeting antivirals (VTAs), which directly (DVTAs) or indi-
rectly (InDVTAs) inhibit the biological function of virally
encoded proteins, and host-targeting antivirals (HTAs) that
inhibit the function of host protein which are utilized by
virus in the life cycle (Lou et al. 2013; Zhou et al. 2013).
With increased knowledge of viral protein and host
factors, great process has achieved signiﬁcantly pro-
gress in the discovery against chronic viral infectious
diseases, the emergence of new virus caused diseases,
and the resistance to traditional antivirals. In the early
stage of antiviral development, the phenotype-based
screening was launched to ﬁnd reagents that can
inhibit the proliferation of virus in the cell-based
assays. With the increasing knowledge of structural
biology and virology, the understanding of the
molecular mechanism of viral proteins or host factors
that can be utilized by virus for the efﬁcient multi-
plication allowed the researchers to design the com-
pounds those can be ﬁtted into the active site of
target protein. In particular, the fragment-based drug
discovery can lead people make new compound from
several fragments binding in different position of the
active site of target protein. However, in the last
10 years, the target-based strategy was challenged.
The difﬁculties on compound synthesis, low bioavail-
ability, poor pharmacokinetic property, and toxicity
result in the low ratio of success. Meanwhile, poor
biology, lack of disease relevant assay, poor target
validation, and lack of biochemical information also
lead to the failure of target-based strategy. Therefore,
the phenotype-based screening returned to the main
track of antiviral discovery in recent years and led to
several great successes in the development of
reagents to treat HCV, HIV-1, Dengue, and other viral
infections. In this work, we used EV71 to present a
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comprehensive system for the phenotype-based dis-
covery of leading compound against viral infection.
OVERALL DESCRIPTION OF ANTIVIRAL INHIBITOR
DISCOVERY SYSTEM
A phenotype-based antiviral discovery pathway can be
generally divided into the early discovery of potential
compound, inhibition effect conformation and evalua-
tion, target discovery, mechanism investigation, com-
pound optimization, and further pharmacological
research (Fig. 1). The general protocol presented here
has been used successfully by our group for the dis-
covery of several antiviral leading compounds with high
potency. Because the compound optimization and
pharmacological research are in very late stage, we
focus on the early stage of antiviral discovery in this
work.
RESULTS
Phenotype screening to discovery potential
inhibitor
We performed the initial screening through a GFP-based
assay (Fig. 2). The intensity of GFP was observed under
the microscope to determine the antiviral activity of
compound (Fig. 2, upper panels). As the control,
Hoechst is usually used to visualize the nuclei, marking
up the host cells, to monitor the virus growth (Fig. 2,
lower panels).
In an initial screening, we select the compounds,
which can protect the host cell against virus infection
(e.g., 50% host cells can survive) at the concentration
lower than 20 lmol/L, for our further validation.
However, this limitation is not a strong cap. It is highly
dependent on the type of virus and cell lines.
The security of inhibitors on cell level
Because the compounds can occasionally hurt host cells
and result in false positives, we would like to check the
cytotoxicity of the compounds selected from the initial
screening to demonstrate the speciﬁcity of the inhibi-
tion. In general, we test the cytotoxicity by using the
cells which support the virus growth, but we also use
Vero cell as a general control to monitor the cytotoxicity
of these compounds. There is no obviously cytotoxicity
of compound on RD cells (Fig. 3).
If the CC50 value is much higher than the concen-
tration that can inhibit virus proliferation of approxi-
mately 20-fold, we believe that this inhibition to virus
growth is speciﬁc and will subsequently measure the
inhibition to the replication of viral genome, the
expression of viral protein, and the production of
mature virus.
Fig. 1 Workﬂow for a
phenotype-based antiviral
discovery system
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The inhibitory activity of compound
We further studied the anti-EV71 activity of compound
by infecting RD cells with EV71 virus. The infected cells
were treated with various concentrations of compound
for 24 h, and the remaining levels of EV71 RNA in RD
cells were determined by qRT-PCR. The results revealed
that the tested compound showed a concentration-
dependent reduction of EV71 RNA in the infected cells
(Fig. 4).
Western blot analysis
We used western blot to monitor the inhibition of virally
encoded protein by compounds. The result showed that
the inhibitor was dose-dependent and the expression of
EV71 VP1, which is the major component of EV71
capsid, was obviously attenuated by the treatment of
suramin. In a contrast, the expression of endogenous
glyceraldehyde-3-phosphate dehydrogenase (GADPH)
was not affected, being indicative that the inhibition of
this inhibitor to EV71 replication was speciﬁc (Fig. 5).
Cell binding assay
The entry stage of EV71 infection can be further sub-
divided into two steps: (1) the attachment of EV71
virion to host cell mediated by functional receptors and
(2) uncoating to release viral genome into host cell. To
further deﬁne the inhibitory mechanism of compound
on EV71 entry, we analyzed the binding afﬁnity of EV71
virion to host cell with the treatment of compound.
We incubated RD cells with EV71 virus with the titer
of tenfold diluted (1:10) and 20-fold diluted (1:20)
standardized viral stocks in the absence or presence of
compound. In the presence of 50 lmol/L compound,
the virus bound to host cell in two conditions decreased
to less than 20% of that seen in the absence of com-
pound. When the concentration of compound dropped
to 20 lmol/L or 10 lmol/L, the bindings to host cell
Fig. 4 EC50/IC50 measured by qRT-PCR method. The levels of
EV71 RNA were quantiﬁed by qRT-PCR at 24 hpi and were
expressed as the percentage of the level of EV71 RNA for the
untreated control cells (the mRNA level of GADPH as an internal
reference). Each data point represents the average for three
replicates in a single experiment
Fig. 2 A GFP-based initial screening assay used for anti-EV71 reagent development. Compounds were added to the RD cells in a
concentration series from high to low and infected by the virus. After 24 h, the expression of GFP (top panel) and the nuclei dyed by
Hoechst (bottom panel) were observed under microscope to deﬁne the effective compound concentration
Fig. 3 The measure of cytotoxicity of a compound. To monitor
cytotoxic effect, the viability cells following compound treatment
were determined using WST-1 based assay and compared to that
of untreated control cells at 24 h post infection (hpi)
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were both rescued. These results revealed that com-
pound directly blocked the attachment of EV71 virion to
host cell (Fig. 6).
Immunoﬂuorescence assay (IFA)
We further examined the internalization of EV71 by
using immunoﬂuorescence (Fig. 7). The RD-sh-control
and RD-sh-cell surface protein cells were infected with
EV71, and endogenous protein and EV71 VP1 proteins
were analyzed by immunoﬂuorescence. In the RD-sh-
control cells infected with wt-EV71, EV71 VP1 was
distributed throughout the cytoplasm at 2 hpi, which
was indicative that the virus particle internalization and
localization with cell surface protein was random
(Fig. 7, panel A–C). In the downregulation of cell surface
protein in the RD-sh-cell surface protein cells infected
with wt-EV71, the localization of wt-EV71 was restric-
ted to the cytoplasm of the perimembrane region at 2
hpi (Fig. 7, panel E–G). We can also observe the colo-
calization of EV71 VP1 with cell surface protein, sug-
gesting that the knockdown of cell surface protein
inhibited the internalization of EV71 and cell surface
protein was accumulated around EV71 virions.
In vitro enzymatic assay: protease
We studied the anti-EV71 3Cpro activity of compound.
The 3Cpro, the best ﬂuorogenic peptide and compound
incubate a few minutes in buffer. The initial velocities of
the enzymatic reactions (within the ﬁrst 5 min) were
determined and ﬁtted to a sigmoidal dose-response
equation with nonlinear regression analysis using the
program GraphPad Prism 5 software. The data from
three independent assays were used as input for Prism
to calculate the IC50 and 95% conﬁdence interval values
(Fig. 8D). The results revealed that the tested com-
pound showed a concentration-dependent reduction of
3Cpro.
In vitro enzymatic assay: polymerase
An in vitro assay was used to test whether compound
functions as a chain terminator to inhibit EV71 genome
replication. This biochemical approach used a primer
extension-based RdRp assay. This assay measures the
incorporation of [a-33P] ATP in the presence of ATP
using polyU as the RNA template. A triphosphate
derivative of compound (ppp-compound) was chemi-
cally synthesized to serve as an RdRp substrate. Addi-
tion of ppp-compound to the RdRp reaction reduced the
amounts of RNA products in a dose-dependent manner.
The results suggested that ppp-compound acts on viral
RdRp to terminate RNA synthesis (Fig. 9).
METHODS
Cell lines, viruses, and reagents
Stable cell lines are essential for antiviral discovery. To
evaluate the inhibition effect, we select one stable cell
line for the initial screening, and two or three cell lines
for further validation. For example, we usually use RD
(human embryonal rhabdomyosarcoma) cell lines for
anti-EV71 drug discovery (Chen et al. 2013; Sun et al.
2012). RD cell is a commercially supplied cell line and
we purchased it from ATCC Company. We culture RD
cell in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
Fig. 5 Western blot analysis to monitor the change of the
expression of viral protein. The inhibition of EV71 VP1 expression
treated with different concentrations of compound, comparing to
the expression of an internal control, GADPH
Fig. 6 Cell binding assay. RD cells were used to compare the cell
binding capacity of EV71 under the treatment with inhibitor at
different concentration (50, 40, 30, 20, and 10 lmol/L, respec-
tively). Two conditions were assessed: tenfold diluted (1:10) and
20-fold diluted (1:20) standardized viral stocks (108 TCID50/mL).
The quantiﬁcation of bound virus was measured by quantitative
real-time RT-PCR assay and expressed as the virus binding by
using 0.5% DMSO as control. Vertical bars indicate mini-
mum/maximum values
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(GIBCO) supplemented with 10% fetal bovine serum
(FBS) (GIBCO) at 37 C in a humidiﬁed incubator with
5% CO2. After the initial screening, we additionally use
the kidney cell of African green monkey (Vero) to fur-
ther validate the inhibition effect. Vero cell is cultured
under the same condition of the culture of RD cell.
Although the cell lines for virus proliferation are highly
dependent on the type of virus, Vero cell has also been
widely used in the detection of chemical’s toxicity.
To evaluate the inhibition effect to various virus
stains, we use two or three virus stains for the entire
pipeline, including a prototype stain and one or two
clinical strains. For example, we use the prototype strain
BrCr (U22521) and a clinical strain AnHui1
(GQ994988.1) of EV71 in our research. For initial
screening, we would like to insert a GFP reporter gene
into the genome of target viral genome. For GFP and
reporter virus, the ﬂuorescent gene was inserted
between the 50UTR and the N-terminus of VP4 gene
with the addition of an EV71 2A protease cleavage site
(ITTLG) at its C-terminus. Upon the cleavage by 2A
protein, the ﬂuorescent protein is released and visible
under a ﬂuorescent microscope. The GFP expression in
the GFP-EV71 reporter virus-infected cells correlates
Fig. 7 Immunoﬂuorescence assay (IFA). Immunoﬂuorescence analysis was performed on RD-sh-control and RD-sh-cell surface protein
cells infected with EV71 at a MOI of 50. After 2 hpi, cells were ﬁxed and stained with anti-cell surface protein (panels A and E, green) and
anti-EV71 VP1 (panels C and G, red) antibodies, and DAPI was used to visualize the nuclei (panels B and F, blue). Panels A–D and E–
H show the same cells. Merged images are shown in panels D and H, respectively
Fig. 8 In vitro enzymatic
assay—protease. IC50 of the
peptidomimetic inhibitors
against the EV71 3C protease.
A Five synthetic peptides used
in enzymatic assay. B Principle
of ﬂuorescence resonance
energy transfer (FRET).
C Curves of different inhibitors
at series concentrations and
times. D The calculation of
IC50 value of one inhibitor
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with viral RNA replication. The wild-type (wt) and
GFP-inserted virus are ampliﬁed and quantiﬁed by the
determination of the 50% tissue culture infective dose
(TCID50) per 1 mL in host cells as previously descri-
bed (Lin et al. 2002), and are used for all
experiments.
The compounds for screening are permanently
stored as powder in -80 C and were initially dis-
solved in dimethyl sulfoxide (DMSO) with a certain
concentration (we prefer 10 mmol/L), and stock
solutions were stored at -20 C. Immediately before
addition, these compounds were diluted to the desired
concentrations using DMEM with 10% FBS. However,
a key issue is often ignored that the compound which
is stored in DMSO at -80 C may have degradation
during long-term storage. This caused several unex-
pected observations in our research (unpublished
result). We suggest that the compounds which are
stored in DMSO solution should be updated one or
two years to avoid degradation.
Phenotype screening
In the discovery of anti-EV71 reagent, we ﬁrst seed
3 9 104 RD cells per well in 96-well microtiter pla-
tes 24 h before experiment and then supply the com-
pounds after serially diluted compounds in the presence
of 10% FBS and 0.5% DMSO to the desired concentra-
tion. After adding compounds, 100 9 TCID50 virus is
used to transfect RD cells for 24 or 48 h, and then we
observed the GFP under microscope.
Cytotoxicity
To monitor the cytotoxic effect of the compounds
selected from anti-EV71 screening assay, the viability of
RD or Vero cells following 24 h of serially diluted
compounds in the presence of 10% FBS and 0.5% DMSO
treatment was determined in 96-well tissue culture
plates using cell proliferation reagent WST-1 (Roche).
Cells are seed at a concentration of 3 9 104 cells/well
with additional compounds at various concentrations
(0.1–200 lmol/L) and are incubated for another 24 h.
After that, WST-1 reagent is supplied to each well for an
incubation of 4 h before shaking thoroughly for 1 min
on a shaker. We can consequently measure the absor-
bance of the samples at 420–480 nm using a microplate
reader.
The viability of cells is plotted by GraphPad Prism 5
software and the percentage of cytotoxicity was calculated
as follows: % cytotoxicity = (1 - (average of compound-
treated cells)/(average of control cells)) 9 100. The con-
centration that 50% cells can survive (CC50) is calculated in
GraphPad Prism 5 software.
Measure EC50/IC50
We usually measure the concentration for 50% of maximal
effect (EC50) or 50% of maximal inhibition (IC50) through
quantitative RT-PCR (qRT-PCR) method to monitor the
changing of viral genomes. In our anti-EV71 assay, 105 RD
cells are seeded in each well of 24-well tissue culture
plates and were allowed to attach in complete culture
medium overnight. The culture mediumwas replaced with
medium containing serially diluted compounds in the
presence of 10% FBS and 0.5% DMSO. After adding
compounds, we use 100 9 TCID50 virus to transfect RD
cells. After the cells were treated for 24 h, total cellular
RNA was isolated by Trizol reagent using standard pro-
tocols. qRT-PCR assay (for primer sequences, GADPH as an
internal control, forward primer 50-CCC ACT CCT CCA CCT
TTG ACG-30 and reverse primer 50-CAC CAC CCT GTT GCT
GTA GCCA-30, EV71 50UTR forward primer 50-TGA ATG
CGG CTA ATC CCA ACT-30 and reverse primer 50-AAG AAA
CAC GGA CAC CCA AAG-30) was performed by QuantiTect
SYBR Green RT-PCR kit (QIAGEN, Valencia, CA) as manu-
facturer protocol. EV71 and GAPDH transcript levels were
determined by DDCT method (Schmittgen and Livak
2008). The percentage of inhibition was calculated as
follows: % inhibition = (1 - (average of compound-
treated cells)/(average of control cells)) 9 100. IC50 is the
concentration of compound at which the EV71 RNA level
in the RD cells is reduced by 50%. The values of EC50 or
IC50 are plotted by the GraphPad Prism 5 software.
Fig. 9 In vitro enzymatic assay—polymerase. A SDS-PAGE of the
reaction products treated with different concentration of com-
pound. B The relative activity of polymerase under increasing
concentration of compound
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Western blot analysis
To monitor the inhibition of virally encoded protein by
compounds, we infect the host cells with virus for 24 or
48 h. Cells are then lysed in a buffer containing
50 mmol/L Tris-HCl, pH 8.0, 150 mmol/L NaCl, 1% NP-
40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate (SDS), 2 mmol/L EDTA, 1 mmol/L NaVO4,
10 mmol/L NaF, and protease inhibitors, and the pro-
tein concentration in the lysates was determined by a
spectrophotometer. Proteins are resolved by sodium
dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred of proteins from gel to NC
membrane (Millipore). NC Membranes were blocked for
4 h with 5% nonfat dry milk solution in Tris-buffered
saline and as thorough removal of the unbound reagents
after each of the binding steps in the procedure. This is
terminated by performing series of washes, and then
blotted with speciﬁc primary antibodies, wash away
excess primary antibodies, and incubate with secondary
antibodies conjugated with horseradish peroxidase.
Proteins were visualized by chemiluminescence and
clarity western ECL substrate (BIO-RAD) (Fig. 5).
Cell binding assay
Cell binding assay can help us to direct measure the
viral attachment to host cells with or without the
treatment of compounds. In our anti-EV71 reagent dis-
covery system, RD were seeded at 1 9 105 RD cells/
well in 24-well plates. After 24 h culture, medium was
removed and cells were washed once with cold phos-
phate buffer saline (PBS). 500 lL of binding buffer (PBS
containing 1% BSA and 0.1% sodium azide) was added
to cell on ice for 10 min and the supernatant was sub-
sequently removed from cells. The 108 TCID50/mL of
virus was prepared. 500 lL of EV71 virus diluted by
DMEM complete medium (dilution fold = 1:10 or 1:20)
with 0.5% DMSO or additionally compound was added.
After 1 h of incubation on ice, unbound virus was
removed by three wash steps with 500 lL PBS and then
cells were lysed in the wells with 500 lL Trizol reagent.
Viral RNA was extracted and detected by qRT-PCR
(Fig. 6). The virus binding assays were performed sys-
tematically in duplicate in two individual experiments
for each condition to avoid false positives.
Target discovery
In the structure or target-based antiviral development,
the target for inhibitor action is clear. But a key question
for the phenotype-based antiviral discovery is what the
exact working target is for antiviral function. This is also
critical for the further investigation of inhibition mech-
anism and the optimization of the inhibitors. The most
potent method for the identiﬁcation of working target is
screening of drug-resistant virus. Since the virus
mutates its genome and protein at speciﬁc position
where the antiviral acts to conquer the drug treatment,
sequencing of the entire viral genome to identify the
mutation helps us to know the working target of the
potential inhibitors.
In our anti-EV71 drug screening assay, RD cells were
seeded at 5 9 105 cells/well in 6-well plates. After 24 h
culture, the media were removed and replaced with
DMEM containing 10% FBS and the inhibitor (the
inhibition is above 90%), 0.5% DMSO as control. After
8 h, virus stain was used to infect RD cells at 0.1 MOI in
media containing inhibitors. During the course of
selection, RD cells were split when a 70%–90% con-
ﬂuence was reached. Fresh media containing inhibitors
were added when the cell culture was split. The virus
replication in the presence of inhibitors was monitored
by CPE at each passage. The viruses demonstrate
apparent cytopathogenic effect (CPE) about 5 to 7 days
in media containing inhibitors or 2 days in media con-
taining 0.5% DMSO after virus infection. Then the cell
supernatants were collected following centrifugation at
4000 g for 5 min and were stored at -80 C as
Virus-P2 (passage 2) virus. Then the RD cells were
treated with inhibitors for 8 h and infected with Virus-
P2 virus at the same condition as above. Until the
experiment was cycling operated for six times, and
the cell supernatant was collected as Virus-P6 (pas-
sage 6) virus. The RD cells were lysed by using
Trizol reagent.
For EV71 RNA resistance mutation analysis, intra-
cellular RNA extraction was performed by using Trizol
reagent (Invitrogen) according to the manufacturer’s
instructions. For reverse transcription PCR, the ﬁrst-
strand cDNA was synthesized by using a gene speciﬁc
primer (50- ACCCCCACCAGTCACATTCACG-30) and Super
Script III First-strand Synthesis System for RT-PCR kit
(Invitrogen) according to the manufacturer’s instruc-
tions. The short RT-PCR products of the resistant EV71
virus or control EV71 virus were ligated into the TA
cloning vector PMD18-T (Takara). For each time point,
multiple individual bacterial colonies were isolated, and
the puriﬁed plasmid DNA was sequenced. The most
mutated sites are very likely to be the drug working
sites and we can test whether the targets are identiﬁed
through drug-resistance screening further.
To conﬁrm, the mutant was approximately over
ﬁvefold higher than the EC50 value for wt-EV71.
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Mechanism investigation
Once the working targets of inhibitors can be deﬁned by
the sequencing of drug-resistant viruses, we would like
to further characterize the inhibition mechanism
through virology and biochemical methods. The virus
life cycle can be simply featured into the entry, repli-
cation and transcription, and maturation and releasing
processes. If the inhibitors function at the entry step, we
use cell binding assay and immunoﬂuorescence assay to
check the binding afﬁnity between virus and host cell or
functional receptors. If the inhibitors function at the
replication and transcription step, the in vitro enzymatic
assays are preferred. We present a general protocol
which we use in anti-EV71 drug screening work.
Immunoﬂuorescence assay (IFA)
We can further directly view the binding of virus to host
cells through IFA assay. RD cells were grown on cover
slips till 50% conﬂuency and infected with EV71 virus.
At the indicated times post infection, cells were washed
with PBS and ﬁxed with 4% paraformaldehyde for
15 min at room temperature, washed, permeabilized
with 0.5% Triton X-100 in PBS for 10 min, washed, and
blocked with 1% normal goat serum in PBS for 30 min,
followed by a 1 h incubation with primary antibodies
1:400 at room temperature. After three washes with
PBS, cells were incubated with FITC- or PE-conjugated
secondary antibodies at a 1:200 dilution for 1 h. After
extensive washing with PBS, cell nuclei were stained
with DAPI. Images were captured by confocal micro-
scopy (Olympus FluoView FV1000 Confocal Microscope
operated by FluoViewTM software) (Fig. 7). If the
treatment of compound obviously causes the accumu-
lation of virus at the host membrane region, this com-
pound is believed to inhibit the entry of virus.
In vitro enzymatic assay: protease
The inhibition of compound to viral transcription and
replication step usually works at viral protease or
polymerase activity. To detect the inhibition to viral
protease activity, we need an in vitro cleavage assay.
There are ﬁve peptides in the experiment (Fig. 8A), and
the cleavage assay was performed in a reaction volume
of 200 to yield a ﬁnal concentration of 5 lmol/L
enzyme and 500 lmol/L peptide, residual volume ﬁlling
with buffer. Cleavage reactions were routinely incubated
at 25 C for 5 min and then terminated by the addition
of an equal volume of 2% triﬂuoroacetic acid. The
samples were analyzed by reverse-phase high-
performance liquid chromatography (HPLC) on a C18
column (4.6 by 250 mm) using a 20-min, 5%–45%
linear gradient of acetonitrile in 0.1% triﬂuoroacetic
acid. The absorbance was monitored at 215 nm. The
area of the product peak was calculated and trans-
formed into a product-peptide concentration, based on
which the efﬁciency of each peptide being processed by
protease could be determined. The cleavage efﬁciency
was deﬁned as the average rate within 5 min of a
selected peptide being cleaved by 5 lmol/L either
protease with an initial peptide concentration of
500 lmol/L. Then the best peptide substrate was
attached with a ﬂuorescence quenching pair, and the
ﬂuorogenic peptide. It was used as the substrate for the
inhibition assay. This peptide contains the proteinase
site, with excitation at 320 nm, and enhanced ﬂuores-
cence could be observed at 405 nm after the cleavage of
the peptide (Fig. 8B). This enabled us to monitor the
peptide cleavage in real time (Fig. 8C). The enzyme
concentration used in measuring Km and Kcat values was
0.5 lmol/L and the substrate concentrations were from
0.5- to 5-fold of an estimated Km value. Substrate con-
centration was determined by using the extinction
coefﬁcients 5438 L/(molcm) at 336 nm (Edans) or
15,100 L/(molcm) at 472 nm (Dabcyl). The initial rates
within 10% substrate consumption at different sub-
strate concentrations were used to calculate the kinetic
parameters using Michaelis-Menten equation ﬁtted with
the KaleidaGraph computer program.
In our anti-EV71 assay, to determine the 50% inhi-
bitory concentrations (IC50) of inhibitors against
9 lmol/L protease, 150 lmol/L ﬂuorescent peptide,
and gradient concentrations of inhibitor were mixed in a
buffer. The initial velocities of the enzymatic reactions
(within the ﬁrst 5 min) were determined and ﬁtted to a
sigmoidal dose-response equation with nonlinear
regression analysis using the program GraphPad Prism
5 software. The data from three independent assays
were used as input for Prism to calculate the IC50 and
95% CI values (Fig. 8D).
In vitro enzymatic assay: polymerase
The inhibition to viral polymerase activity can be eval-
uated by measuring the extension of viral genome. For
example, in our anti-EV71 drug discovery system, the
replication process of EV71 presents a template-
dependent manner, by using a small stem loop structure
(cis-acting replication element, CRE) as the natural
template and the protein VPg as a primer(Chen et al.
2013; Sun et al. 2012). For the RdRp assay, the uridy-
lylation assay mixture (20 lL), containing 50 mmol/L
HEPES (pH 7.5), 0.5 mmol/L magnesium chloride, 7%
glycerol, 1 lg of CRE, 50 lmol/L VPg, 1 lg of EV71 3D,
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and 1 lCi [a-32P]UTP, was incubated at 30 C for 1 h.
After the reaction, the aliquots were mixed with the
same volume of 2 9 Tris-Tricine SDS buffer containing
100 mmol/L Tris-HCL (pH 6.8), 20% (v/v) glycerol, 8%
(w/v) SDS, 5% b-mercaptoethanol, and 0.05% bro-
mophenol blue. Tris-Tricine SDS-PAGE, using 4% stack-
ing gel (29:1 acrylamide-bisacrylamide, pH 8.45
1 mol/L Tris-HCl, and 0.1% SDS), and 16% separating
gel (29:1 acrylamide-bisacrylamide, pH 8.45 1 mol/L
Tris-HCl, 0.1% SDS, and 10% v/v glycerol), was used to
separate the reaction products (Fig. 9A). Phosphorimager
(Molecular Dynamics, Storm860)was used to capture the
images. The image ﬁle was applied in IMAGEQUANT TL
(GEHealthcare) software to detect the strand product and
the relative inhibitory activity (Fig. 9B).
Leading compound validation and further
pharmacological research
The process of ﬁnding a new drug against a chosen
target for a particular disease usually involves high-
throughput screening (HTS), wherein large libraries of
chemicals are tested for their ability to modify the tar-
get. Another important function of HTS is to show how
selective the compounds are for the chosen target. The
ideal is to ﬁnd a molecule which will interfere with only
the chosen target, but not other, related targets. To this
end, other screening runs will be made to see whether
the ‘‘hits’’ against the chosen target will interfere with
other related targets—this is the process of cross-
screening. All these processes will require several iter-
ative screening runs. Once a lead compound series has
been established with sufﬁcient target potency and
selectivity and favorable drug-like properties, one or
two compounds will then be proposed for drug devel-
opment. The best of these is generally called the lead
compound.
After the leading compound with reasonable inhibi-
tion to virus proliferation with clear mechanism could
be identiﬁed from the comprehensive antiviral
discovery system described above, we pass through our
leading compound to the chemists to modify the
chemical structure and re-cycle these new compounds
in our system to further validate the improvement to
the inhibition effect and lower the cytotoxicity. Once a
leading compound can be generated with good potency
and low cytotoxicity, it will be transferred to pharma-
cologist to verify the pharmacological features, includ-
ing the bioavailability, pharmacokinetic property, etc.
We have to notify that although the ﬁnding of a leading
compound with potent inhibition effect to virus, the
ratio to produce a ﬁnal antiviral drug is still very limited
due to the poor pharmacological features and we have
to keep a long way in the battle with virus.
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